Premium
Long‐term alpha interferon treatment is effective on anaemia and significantly reduces iron overload in congenital dyserythropoiesis type I
Author(s) -
LavabreBertrand Thierry,
Ramos Jeanne,
Delfour Christophe,
Henry Laurent,
Guiraud Isabelle,
Carillo Serge,
Wagner André,
Bureau Jean Paul,
Blanc Pierre
Publication year - 2004
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2004.00310.x
Subject(s) - interferon , medicine , alpha interferon , ferritin , gastroenterology , immunology
Interferon has been shown to be an effective treatment of congenital dyserythropoiesis type I (CDA‐I), but the optimal dose and the feasibility of this treatment remains to be determined. Here, in a 9‐yr follow‐up of a single patient, we show that interferon remains active during such a long period. The optimal dose of conventional alpha interferon could be evaluated at 2 million units twice a week. Pegylated interferon could be used as well at a dose of 30 μ g/wk. During interferon treatment, serum and erythrocyte ferritin levels decreased progressively, and remained inversely correlated with haemoglobin levels. On repeated liver biopsies, iron overload could be normalized. Low dose interferon is a long‐term treatment of CDA‐I, and allows a significant decrease in iron overload, that could be interesting even in patients who are only moderately anaemic.